Scott Plotkin, MD, reviews data from a phase II study on brigatinib, a multi tyrosine kinase inhibitor, across various tumor types in patients with NF2-related schwannomatosis.
Scott Plotkin, MD, PhD
Advertisement
Articles by Scott Plotkin, MD, PhD
Advertisement
Latest Updated Articles
Brigatinib in NF2-Related Schwannomatosis with Progressive TumorsPublished: August 22nd 2024 | Updated: August 29th 2024
- Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Published: August 22nd 2024 | Updated: August 29th 2024
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5